Ruiz-Gastélum E, Díaz-Aragón A, Álvarez-López H

Idioma: Inglés [English version]
Referencias bibliográficas: 19
Paginas: s231-235
Archivo PDF: 321.06 Kb.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139 (25): e1082-e1143.

2. Packard CJ, Boren J, Taskinen MR. Causes and consequences of hypertriglyceridemia. Front Endocrinol (Lausanne). 2020; 11: 252.

3. Hernández-Mijares A, Ascaso JF, Blasco M, Brea A, Díaz A, Mantilla T et al. Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects. Clin Investig Arterioscler. 2019; 31 (2): 75-88.

4. Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016; 118 (4): 547-563.

5. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol. 1992; 70 (19): 3H-9H.

6. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996; 77 (14): 1179-1184.

7. Liu J, Zeng FF, Liu ZM, Zhang CX, Ling WH, Chen YM. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis. 2013; 12: 159.

8. Klempfner R, Erez A, Sagit BZ, Goldenberg I, Fisman E, Kopel E et al. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the bezafibrate infarction prevention study and registry. Circ Cardiovasc Qual Outcomes. 2016; 9 (2): 100-108.

9. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E; PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008; 51 (7): 724-730.

10. Nordestgaard BG. A test in context: lipid profile, fasting versus nonfasting. J Am Coll Cardiol. 2017; 70 (13): 1637-1646.

11. Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020; 41 (1): 99-109c.

12. Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017; 69 (16): 2054-2063.

13. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013; 61 (4): 427-436.

14. Wulff AB, Nordestgaard BG, Tybjærg-Hansen A. APOC3 loss-of-function mutations, remnant cholesterol, low-density lipoprotein cholesterol, and cardiovascular risk: mediation- and meta-analyses of 137 895 individuals. Arterioscler Thromb Vasc Biol. 2018; 38 (3): 660-668.

15. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020; 41 (24): 2313-2330.

16. Patel PN, Patel SM, Bhatt DL. Cardiovascular risk reduction with icosapent ethyl. Curr Opin Cardiol. 2019; 34 (6): 721-727.

17. Handelsman Y, Shapiro MD. Triglycerides, atherosclerosis, and cardiovascular outcome studies: focus on omega-3 fatty acids. Endocr Pract. 2017; 23 (1): 100-112.

18. Basu D, Bornfeldt KE. Hypertriglyceridemia and atherosclerosis: using human research to guide mechanistic studies in animal models. Front Endocrinol (Lausanne). 2020; 11: 504.

19. Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev. 2019; 40 (2): 537-557.